AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04149275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
Study NCT06301243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Low physical activity level prior to the exercise intervention.
Study NCT06301243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactivity
Description: Low physical activity level prior to the exercise intervention.
Study NCT05542901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Joint Position Sense Analysis
Description: The Xsens DOT Motion Capture System will be used to analyze joint position sense.
Study NCT06355752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling of lumbar iliocostalis muscle
Description: Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow
Study NCT06355752 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling lumbar iliocostalis muscle
Description: Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow
Study NCT06511245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Randomisation
Description: Technique assigned through randomization
Study NCT05352776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor EV-ICD Lead
Description: Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
Study NCT04765072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Patient Navigation Intervention
Description: Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
Study NCT04765072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Survivorship Visit Intervention
Description: Individualized survivorship care plan
Study NCT06561191 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hemodialysis mode, dialyzer type
Description: Change of hemodialysis mode and dialyzer type
Study NCT06561061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: Dispersible (20 mg) tablet
Study NCT06561061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispersible tablet
Study NCT03675633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FEUrea
Description: FEUrea in decompansated liver cirrhosis
Study NCT06219031 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06446713 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image guided hybrid hyper-fractioned dose escalation with proton therapy
Description: Radiation: Image-guided hybrid hyper-fractioned dose escalation with proton therapy~The investigational radiation regime will be administered in a two-part schedule:~* The first 4 weeks (i.e. first 20 fractions) of the radiation treatment of the pathological tumor will be according to the conventional clinical standard with proton therapy: 20x 2 Gy to the CTV70 and 20 x 1.55 Gy to the CTV54.~* In week 4 (\~ fraction 16) GTV80 will be determined on conventional weekly CT and additional MR imaging (conventional clinical protocol). Only this adapted tumor volume, the so-called GTV80, will receive the dose escalation (i.e., 80.5 Gy).~* In the last 3 weeks (last 15 fractions) patients will be radiated twice per day (i.e. hyperfractionation). The GTV80, CTV70 and CTV54 will receive 1.55 Gy in the morning, and the GTV80 and CTV70 will receive additional dose in the afternoon.
Study NCT05114512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAPTOR protocol: hybrid in-person + telehealth physical therapy services
Description: All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
Study NCT05199038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide infusion for 2 days in patients with bleeding esophageal varices.
Study NCT05199038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide infusion for 2 days in patients with bleeding esophageal varices.
Study NCT04097184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation with non-implanted electrodes
Description: Neurostimulation with non-implanted electrodes
Study NCT04097184 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostimulation with non-implanted electrodes
Description: Neurostimulation with non-implanted electrodes
Study NCT06369051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-employment support intervention
Description: A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
Study NCT05823077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot
Description: The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
Study NCT05823077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
Study NCT05961384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: a blood pressure lowering drug, oral dose
Study NCT05365464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Pill
Description: Orally active progesterone
Study NCT05365464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Given by subcutaneous injection
Study NCT05611424 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.
Study NCT05290974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self exploring of available online material on supraclavicular brachial plexus block
Description: Potential new method of learning a specific regional anesthesia technique
Study NCT05290974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in-person teaching on supraclavicular brachial plexus block
Description: Conventional method of learning a specific regional anesthesia technique
Study NCT05617547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse Oximeter (Massimo)
Description: The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
Study NCT05040490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex as reversal drugs
Description: use sugammadex to reverse neuromuscular blockade
Study NCT05808127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainTracker
Description: The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
Study NCT01637571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexilant
Description: 60mg of Dexilant QD for 12 weeks
Study NCT01637571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexilant Placebo
Description: 60mg of Dexilant placebo QD for 12 weeks
Study NCT05344274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Angiography
Description: Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
Study NCT05344274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isocapnic Oxygen
Description: Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
Study NCT05344274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Description: Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
Study NCT04817800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Description: It will be nasaly administered
Study NCT04817800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Description: It will be nasaly administered
Study NCT06035549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Digital Resilience-Building
Description: The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
Study NCT05625971 — intervention group
Intervention type: OTHER
Intervention: MRD Assessment
Description: MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
Study NCT04842890 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Pencil Beam Scanning Proton SBRT
Description: The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
Study NCT05013229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IcoSema
Description: Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
Study NCT05013229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Study NCT05013229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Study NCT06038032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital wellness platform
Description: A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
Study NCT06038032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online healthcare professional support
Description: Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
Study NCT06289881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafill-Test product
Description: Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
Study NCT06289881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafill-Reference product
Description: Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
Study NCT05198362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator
Study NCT05198362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tesomet
Description: Fixed-dose combination
Study NCT05198362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination
Study NCT06569264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF
Description: Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
Study NCT06569264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using vitamin C with dentin graft and i-PRF
Description: Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
Study NCT04619082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide 25 mg once per day for one year
Study NCT05178979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
Study NCT06162234 — intervention group
Intervention type: OTHER
Intervention: observational
Description: none (observational study)
Study NCT06367270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressured Intraperitoneal Aerosol Chemotherapy
Description: PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
Study NCT06494982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
Description: Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
Study NCT06494982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Description: Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Study NCT05467150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
Study NCT05185128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS social skills intervention
Description: The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
Study NCT06408298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 400Mg Tab
Description: hydroxychloroquine sulfate tablet
Study NCT06408298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablet
Study NCT06363955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbamide Peroxide Mouthwash
Description: The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
Study NCT06363955 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
Study NCT00917982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vision therapy
Study NCT04867330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment arm
Description: Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
Study NCT05877196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT)
Description: Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
Study NCT04983953 — intervention group
Intervention type: DEVICE
Intervention: cHS
Description: Clinical decision support system for diagnosing intracranial haemorrhage
Study NCT05877196 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chair-based Stretch
Description: Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
Study NCT05877196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Description: Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
Study NCT05877196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Aerobic Resistance Exercise (CARE)
Description: 6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
Study NCT06032416 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Preoperative CT Scan
Description: Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
Study NCT05597306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be administered orally once daily via capsule.